ArticleNutrients2023
Comparison of the Effects of Monounsaturated Fatty Acids and Polyunsaturated Fatty Acids on Liver Lipid Disorders in Obese Mice.
Article in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 42 citations in OpenAlex.
- Recent Advances in Food Allergens and Emerging Biosensing Technologies.Comprehensive reviews in food science and food safety · 2026Review
- Sanzi Sijun Formula Alleviates Lipotoxic Liver Injury in Metabolic Dysfunction-Associated Steatotic Liver Disease via AMPK/SIRT1 Signaling Pathway.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Impact of drying on yield and composition of extracellular vesicles from Centella asiatica.Scientific reports · 2026Article
- Rational Design of a Functional Fatty Acid Component for Alleviating Western Diet-Induced Insulin Resistance and Glycolipid Metabolism Disorders.Foods (Basel, Switzerland) · 2026Article
- Plasma-targeted proteomic and lipidomic profiling of MASLD, MASH, and hepatitis C virus infection.Clinical proteomics · 2026Article
- Polyunsaturated fatty acids as a potential preventive and therapeutic intervention for metabolic dysfunction-associated steatotic liver disease and its progression to hepatocellular carcinoma.Frontiers in nutrition · 2026Review
- Fish Oil Present in High-Fat Diet, Unlike Other Fats, Attenuates Oxidative Stress and Activates Autophagy in Murine Adipose Tissue.Nutrients · 2025Article
- The Influence of the Dietary Lipid Level on Growth Performance, Lipid Metabolism, Oxidative Response and Hepatopancreatic Health inAnimals : an open access journal from MDPI · 2025Article
- Spatial metabolomics to profile metabolic reprogramming of liver inParasitology · 2025Article
- Article
- Autolysosomal Dysfunction in Obesity-induced Metabolic Inflammation and Related Disorders.Current obesity reports · 2025Review
- Mediterranean diet improves liver health but does not protect against azoxymethane-induced colon tumorigenesis compared to Western diet in A/J mice.Experimental and molecular pathology · 2025Article
- Sex-specific effect of dietary fatty acids on non-alcoholic fatty liver disease.Frontiers in nutrition · 2025Article
- Article
- Relationship Between Dietary Nutrient Intake and Autophagy-Related Genes in Obese Humans: A Narrative Review.Nutrients · 2024Review
- Impact of Plant Oil Supplementation on Lipid Production and Fatty Acid Composition inMicroorganisms · 2024Article
- Updated mechanisms of MASLD pathogenesis.Lipids in health and disease · 2024Review
- Investigating mouse hepatic lipidome dysregulation following exposure to emerging per- and polyfluoroalkyl substances (PFAS).Chemosphere · 2024Article
- Article
- New insights into metabolic dysfunction-associated steatotic liver disease and oxidative balance score.Frontiers in nutrition · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
Obesity is a recognized epidemic worldwide, and the accumulation of excess free saturated fatty acids (SFAs) in cells induces cellular lipotoxic damage and increases the risk of a wide spectrum of metabolic diseases including type 2 diabetes (T2D) and nonalcoholic fatty liver disease (NAFLD). Monounsaturated fatty acids (MUFAs) and polyunsaturated fatty acids (PUFAs) have been reported to combat SFA-induced cellular damage. However, the comparative studies of the two types of unsaturated fatty acids (UFAs) are still limited. We investigated the effects of different MUFAs and PUFAs in the human hepatocyte line L-02 cells in vitro, and in high-fat-diet (HFD)-induced obese C57BL/6 mice in vivo. The results of the in vitro study showed that SFAs induced significant cellular lipotoxic damage, but the combination of MUFAs/PUFAs with SFAs significantly improved the impaired cell viability. Particularly, oleic acid (OA) was superior to eicosapentaenoic acid (EPA), Docosahexaenoic acid (DHA), and arachidonic acid (AA) in terms of its anti-apoptotic effect and inhibition of endoplasmic reticulum (ER) stress. In vivo, both olive-oil-enriched (HFD + OO) and fish-oil-enriched high-fat diets (HFD + FO) reduced hepatic steatosis and improved insulin sensitivity in obese mice. However, FO induced an abnormal increase in serum aspartate aminotransferase (AST) and an increase in the oxidative stress indicator Malondialdehyde (MDA). Liver-targeted lipidomic analysis showed that liver lipid metabolites under the two types of UFA dietary interventions differed from the HFD group, modulating the abundance of some lipid metabolites such as triglycerides (TGs) and glycerophospholipids. Furthermore, the FO diet significantly increased the abundance of the associated FA 20:5 long-chain lipid metabolites, whereas the OO diet regulated the unsaturation of all fatty acids in general and increased the abundance of FA 18:1 in the overall lipid metabolites, especially TGs, which may primarily contribute to the FO, and OO drove protection in NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.